Journal of Clinical and Experimental Cardiology
Open Access

Abstract

EphA2 Receptor Activation by Doxazosin as Potential Therapeutic Strategy Beneficial for Myocardial Infarction and Ischemia-Reperfusion Injury

Kamaldeep Kaur*, Nitish Sharma, Komal Kashyap, Puja Gulati, R. K. Dhawan and Nirmal Singh

Myocardial Infarction (MI) is caused by prolonged ischemia resulting in necrosis to a portion of myocardium. Timely reperfusion to restore blood flow to ischemic myocardium is only mainstay therapy. Experimental models that mimic human Myocardial infarction include permanent closure of Left Anterior Descending coronary artery (LAD). To explore the role of EphA2 receptors and investigate the novel protective role of Doxazosin as EphA2 agonist in MI in vivo, in rats anesthetized with ketamine 80 mg/kg and xylazine 12 mg/kg i.p., intubated with endotracheal cannula using an otoscope under ventilator-assisted ventilation with extrinsic Positive End-Expiratory Pressure (PEEP), LAD ligation was performed. After LAD ligation, animals survived 4 days post-MI; biomarkers of infarction Troponin T and Troponin I and histopathological findings were performed. Doxazosin administered at low dose intravenously immediately after LAD ligation produced cardioprotective effect as manifested by reduced infarct size and Troponin T and Troponin I levels. Dot blot analysis revealed these effects were produced by activation of EphA2 receptors by Doxazosin.

Published Date: 2026-05-20; Received Date: 2025-11-15